Abstract Library

#4625 Efficacy and safety of capecitabine-temozolomide (CAPTEM) regimen in patients with neuroendocrine neoplasms – A systematic review and experience from NETwerk, a Belgian ENETS Center of Excellence

Introduction: Current treatment guidelines remain inconclusive due to scarcity of data regarding the optimal systemic treatment for metastatic gastroenteropancreatic (GEP) neuroendocrine tumours (NET) grade 3 and aggressive GEP-NET grade 2. Similarly, for metastatic pulmonary typical (TC) and atypical carcinoids (AC), the indication for chemotherapy is unclear. Recent evidence highlights a promising role for CAPTEM, combining temozolomide (TEM) with capecitabine (CAP), showing encouraging antitumoural activity and safety profiles for these indications.

Conference:

Presenting Author: Chhajlani S

Authors: Chhajlani S, Lambrechts C, Islam O, de Weerdt C, Verbruggen L,

Keywords: capecitabine, temozolomide, CAPTEM, GEP-NET, pulmonary NEN, safety, efficacy, systematic review,

#4101 Pulmonary neuroendocrine tumors – Symptomatology, tumor characteristics, treatment strategies, and long-term outcomes in 37 Patients

Introduction: Pulmonary Neuroendocrine Tumors (NET) constitute a complex group of diseases with varied clinical manifestations and no definitive diagnostic and treatment guidelines.

Conference:

Presenting Author: Krishna B

Authors: Jain D, Eshpuniyani P, Deshpande R, Sharma S, Krishna B,

Keywords: epidemiology, pulmonary NET, lobectomy, prognosis,

#4006 Efficacy, safety and prognostic factors of Capecitabine plus Temozolomide regimen in patients with thymic neuroendocrine neoplasms

Introduction: Thymic neuroendocrine neoplasms (T-NENs) are rare mediastinal malignancies that lack established treatment guidelines. While the Capecitabine and Temozolomide (CapTem) regimen has demonstrated significant efficacy in patients with pancreatic NENs, its applicability and effectiveness in treating T-NENs remain underexplored.

Conference:

Presenting Author: Liu M

Authors: Liu M, Yan X, Lin X, Chen L, Wang Y,

Keywords: Capecitabine plus Temozolomide, Thymic Neuroendocrine Neoplasm, CapTem, T-NEN,

#3248 A single institution experience with peptide receptor radionuclide therapy (PRRT) in advanced pheochromocytoma and paraganglioma

Introduction: Pheochromocytomas and parangliomas (PPGLs) are very rare tumors. Due to their heterogenicity, there is a lack of treatment guidelines, and therapy options generally are very limited.

Conference: 18th Annual ENETS Concerence (2021)

Presenting Author: Duan H

Authors: Duan H, Ferri V, Fisher G, Shaheen S, Davidzon G,

Keywords: paraganglioma, pheochromocytoma, PRRT, 177Lu-Dotatate,

#3130 Metastatic grade 3 gastric neuroendocrine tumor expressing somatostatin receptor in Multiple Endocrine Neoplasia Type 1 (MEN1) syndrome

Introduction: Gastroenteropancreatic neuroendocrine neoplasms (GEP-NENs) can occur in 30-70% of patients with MEN1. However, only 1% of GEP-NENs are Grade 3 (G3). Treatment for advanced GEP-NENs in MEN1 is based on the treatment guidelines for sporadic GEP-NENs.

Conference: 18th Annual ENETS Concerence (2021)

Presenting Author:

Authors: Graf A, Welch J, Mandl A, Parekh V, Cochran C,

Keywords: case report, multiple endocrine neoplasia type 1, gastroenteropancreatic tumor grade 3,